A prospective pilot study of 89Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy

Journal of Urology

Volumn 191, Issue 5, 2014, Pages 1439-1445

  Osborne, Joseph R ^a   Green, David A ^b   Spratt, Daniel E ^a   Lyashchenko, Serge ^a   Fareedy, Shoaib B ^a   Robinson, Brian D ^b   Beattie, Bradley J ^a   Jain, Manu ^b   Lewis, Jason S ^a   Christos, Paul ^b   Larson, Steven M ^a   Bander, Neil H ^b   Scherr, Douglas S ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

glutamate carboxypeptidase II; human; J591 monoclonal antibody; positron emission tomography; prostatic neoplasms; zirconium

Indexed keywords

MONOCLONAL ANTIBODY J591; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; ZIRCONIUM; MONOCLONAL ANTIBODY J591 ZR 98; TRACER; UNCLASSIFIED DRUG; ZIRCONIUM DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER SURGERY; CLINICAL ARTICLE; COHORT ANALYSIS; EX VIVO STUDY; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; TUMOR VOLUME; WHOLE BODY PET; NUCLEAR MAGNETIC RESONANCE SCANNER; POSITRON EMISSION TOMOGRAPHY; TREATMENT RESPONSE;

GLUTAMATE CARBOXYPEPTIDASE II; HUMAN; J591 MONOCLONAL ANTIBODY; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; ZIRCONIUM;

ANTIBODIES, MONOCLONAL; ANTIGENS, SURFACE; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOISOTOPES; ZIRCONIUM;

EID: 84899103424     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2013.10.041     Document Type: Article

References (24)

1. T. Vo, M.D. Rifkin, and T.L. Peters Should ultrasound criteria of the prostate be redefined to better evaluate when and where to biopsy Ultrasound Q 17 2001 171
2. R.K. Nam, R. Saskin, and Y. Lee et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy J Urol 189 suppl. 2013 S12
3. N.B. Delongchamps, M. Rouanne, and T. Flam et al. Multiparametric magnetic resonance imaging for the detection and localization of prostate cancer: combination of T2-weighted, dynamic contrast-enhanced and diffusion-weighted imaging BJU Int 107 2011 1411
4. S. Edge, D.R. Byrd, and C.C. Compton et al. AJCC Staging Manual, 7th ed 2010 Springer New York
5. L.M. Wu, J.R. Xu, and Y.Q. Ye et al. The clinical value of diffusion-weighted imaging in combination with T2-weighted imaging in diagnosing prostate carcinoma: a systematic review and meta-analysis AJR Am J Roentgenol 199 2012 103
6. G. Mowatt, G. Scotland, and C. Boachie et al. The diagnostic accuracy and cost-effectiveness of magnetic resonance spectroscopy and enhanced magnetic resonance imaging techniques in aiding the localisation of prostate abnormalities for biopsy: a systematic review and economic evaluation Health Technol Assess 17 2013 1
7. J.J. Fox, H. Schoder, and S.M. Larson Molecular imaging of prostate cancer Curr Opin Urol 22 2012 320
8. M. Souvatzoglou, G. Weirich, and S. Schwarzenboeck et al. The sensitivity of [11C]choline PET/CT to localize prostate cancer depends on the tumor configuration Clin Cancer Res 17 2011 3751
9. G. Bauman, T. Belhocine, and M. Kovacs et al. 18F-fluorocholine for prostate cancer imaging: a systematic review of the literature Prostate Cancer Prostatic Dis 15 2012 45
10. B.J. Krause, M. Souvatzoglou, and M. Tuncel et al. The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer Eur J Nucl Med Mol Imaging 35 2008 18
11. M. Haseebuddin, F. Dehdashti, and B.A. Siegel et al. 11C-acetate PET/CT before radical prostatectomy: nodal staging and treatment failure prediction J Nucl Med 54 2013 699
12. N.H. Bander Technology insight: monoclonal antibody imaging of prostate cancer Nat Clin Pract Urol 3 2006 216
13. S. Perner, M.D. Hofer, and R. Kim et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression Hum Pathol 38 2007 696
14. G.L. Wright, B.M. Grob, and C. Haley et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy Urology 48 1996 326
15. J.S. Ross, C.E. Sheehan, and H.A. Fisher et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer Clin Cancer Res 9 2003 6357
16. S. Minner, C. Wittmer, and M. Graefen et al. High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer Prostate 71 2011 281
17. H. Liu, P. Moy, and S. Kim et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium Cancer Res 57 1997 3629
18. N.H. Bander, E.J. Trabulsi, and L. Kostakoglu et al. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen J Urol 170 2003 1717
19. M.I. Milowsky, D.M. Nanus, and L. Kostakoglu et al. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer J Clin Oncol 22 2004 2522
20. N.H. Bander, M.I. Milowsky, and D.M. Nanus et al. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer J Clin Oncol 23 2005 4591
21. S.T. Tagawa, M.I. Milowsky, and M.J. Morris et al. Phase II study of lutetium-177 labeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 for metastatic castration-resistant prostate cancer Clin Cancer Res 19 2013 5182
22. 177Lu-J591) in patients (pts) with metastatic castration-resistant prostate cancer (metCRPC) J Clin Oncol 28 suppl. 2010 7s
23. J. Crook, S. Robertson, and G. Collin et al. Clinical relevance of trans-rectal ultrasound, biopsy, and serum prostate-specific antigen following external beam radiotherapy for carcinoma of the prostate Int J Radiat Oncol Biol Phys 27 1993 31
24. 89Zr J591 immunoPET imaging in patients with prostate cancer (abstr 287) J Nucl Med 54 2013 287